Kirkland Advises Akorn in $440 Million Acquisition of VersaPharm

Kirkland & Ellis LLP advised Akorn, Inc. (Nasdaq: AKRX) on its definitive agreement to acquire VPI Holdings Corp., the parent company of VersaPharm Incorporated, for $440 million in cash.

Akorn, Inc. is a niche pharmaceutical company engaged in the development, manufacture and marketing of multi-source and branded pharmaceuticals. VersaPharm is a privately-held developer and marketer of multi-source prescription pharmaceuticals. The acquisition will be subject to customary conditions and is anticipated to close in the third quarter of 2014.

The Kirkland deal team was led by Chicago corporate partner Keith Crow and New York corporate partner Joshua Zachariah and included partner Douglas Kurtenbach and corporate associate Christine Bedi, both based in Chicago.